featured
Larotrectinib in TRK Fusion–Positive Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Larotrectinib in Patients With TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials
Lancet Oncol 2020 Feb 24;[EPub Ahead of Print], DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, CM van Tilburg, R Nagasubramanian, JD Berlin, N Federman, L Mascarenhas, B Geoerger, A Dowlati, AS Pappo, S Bielack, F Doz, R McDermott, JD Patel, RJ Schilder, M Tahara, SM Pfister, O Witt, M Ladanyi, ER Rudzinski, S Nanda, BH Childs, TW Laetsch, DM Hyman, A DrilonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.